A MAJOR drug being used in Bahrain to treat Covid-19 is effective against all mutations of the Omicron variant, according to a new study.
Sotrovimab – developed by UK’s GlaxoSmithKline (GSK) and US firm Vir Biotechnology – also reduces the chances of hospitalisation and death in patients with mild to moderate Covid-19 symptoms by 79 per cent, the in-house trial by GSK revealed .
&uuid=(email))